» Articles » PMID: 35326638

WISP2/CCN5 Suppresses Vasculogenic Mimicry Through Inhibition of YAP/TAZ Signaling in Breast Cancer Cells

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2022 Mar 25
PMID 35326638
Authors
Affiliations
Soon will be listed here.
Abstract

Vasculogenic mimicry (VM) formed by aggressive tumor cells to create vascular networks connected with the endothelial cells, plays an important role in breast cancer progression. WISP2 has been considered as a tumor suppressor protein; however, the relationship between WISP2 and VM formation remains unclear. We used the in vitro tube formation assay and in vivo immunohistochemical analysis in a mouse model, and human breast tumors were used to evaluate the effect of WISP2 on VM formation. Here we report that WISP2 acts as a potent inhibitor of VM formation in breast cancer. Enforced expression of WISP2 decreased network formation while knockdown of WISP2 increased VM. Mechanistically, WISP2 increased retention of oncogenic activators YAP/TAZ in cytoplasm, leading to decreased expression of the angiogenic factor CYR61. Studies using an in vivo mouse model and human breast tumors confirmed the in vitro cell lines data. In conclusion, our results indicate that WISP2 may play a critical role in VM and highlight the critical role of WISP2 as a tumor suppressor.

Citing Articles

Deciphering MOSPD1's impact on breast cancer progression and therapeutic response.

Jiang Y, Li H, Wu S, Jiang B, Zeng L, Tang Y Biol Direct. 2024; 19(1):88.

PMID: 39369222 PMC: 11453086. DOI: 10.1186/s13062-024-00531-9.


Vascular mimicry as a facilitator of melanoma brain metastasis.

Provance O, Oria V, Tran T, Caulfield J, Zito C, Aguirre-Ducler A Cell Mol Life Sci. 2024; 81(1):188.

PMID: 38635031 PMC: 11026261. DOI: 10.1007/s00018-024-05217-z.


CCN proteins: opportunities for clinical studies-a personal perspective.

Yeger H J Cell Commun Signal. 2023; 17(2):333-352.

PMID: 37195381 PMC: 10326213. DOI: 10.1007/s12079-023-00761-y.


PARP Inhibitor Inhibits the Vasculogenic Mimicry through a NF-κB-PTX3 Axis Signaling in Breast Cancer Cells.

Chivot J, Ferrand N, Fert A, Van Dreden P, Morichon R, Sabbah M Int J Mol Sci. 2022; 23(24).

PMID: 36555812 PMC: 9785325. DOI: 10.3390/ijms232416171.

References
1.
Wei C, Wang Y, Li X . The role of Hippo signal pathway in breast cancer metastasis. Onco Targets Ther. 2018; 11:2185-2193. PMC: 5909795. DOI: 10.2147/OTT.S157058. View

2.
Shi Z, Chen Z, Han Y, Zhu H, Lyu M, Zhang H . WISP2 promotes cell proliferation via targeting ERK and YAP in ovarian cancer cells. J Ovarian Res. 2020; 13(1):85. PMC: 7382796. DOI: 10.1186/s13048-020-00687-8. View

3.
Babic A, Kireeva M, Kolesnikova T, Lau L . CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci U S A. 1998; 95(11):6355-60. PMC: 27701. DOI: 10.1073/pnas.95.11.6355. View

4.
Ferrand N, Gnanapragasam A, Dorothee G, Redeuilh G, Larsen A, Sabbah M . Loss of WISP2/CCN5 in estrogen-dependent MCF7 human breast cancer cells promotes a stem-like cell phenotype. PLoS One. 2014; 9(2):e87878. PMC: 3912128. DOI: 10.1371/journal.pone.0087878. View

5.
Ping Y, Bian X . Cancer stem cells switch on tumor neovascularization. Curr Mol Med. 2010; 11(1):69-75. DOI: 10.2174/156652411794474383. View